Options for the treatment of acute myeloid leukemia (AML) are rapidly expanding, says Amir Fathi, MD, associate professor of medicine at Harvard Medical School in Boston and program director of the Center for Leukemia at Massachusetts General Hospital. “Over the course of the last 10 to 12 years, there have been a series of approvals, predominantly for targeted therapies,” he explains. Speaking with Robert A. Figlin, MD, the interim director of Cedars-Sinai Cancer in Los Angeles and Steven Spielberg Family Chair in Hematology-Oncology, Dr. Fathi outlines how and when to look for mutations in AML and key considerations for various targeted therapies. He also shares what developments he is anticipating. “I’m most excited about where we’re moving in the upfront setting.”

Dr. Fathi reported various financial relationships.

Dr. Figlin reported various financial relationships.